Filtered By:
Condition: Multidrug Resistance

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 957 results found since Jan 2013.

siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
Authors: Montazami N, Kheir Andish M, Majidi J, Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar MA, Khaze V, Mansoori B, Baghbani E, Baradaran B Abstract One of the most challenging aspects of colon cancer therapy is rapid acquisition of multidrug resistant phenotype. The multidrug resistance gene 1 (MDR1) product, p—glycoprotein (P—gp), pump out a variety of anticancer agents from the cell, giving rise to a general drug resistance against chemotherapeutic agents. The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of ox...
Source: Cellular and Molecular Biology - December 2, 2015 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Abstract Multidrug resistance (MDR) significantly decreases the therapeutic efficiency of anti-cancer drugs. Its reversal could serve as a potential method to restore the chemotherapeutic efficiency. Downregulation of MDR-related proteins with a small interfering RNA (siRNA) is a promising way to reverse the MDR effect. Additionally, delivery of small molecule therapeutics simultaneously with siRNA can enhance the efficiency of chemotherapy by dual action in MDR cell lines. Here, we conjugated the dendrimer, generation 4 polyamidoamine (G4 PAMAM), with a polyethylene glycol (PEG)-phospholipid copolymer. The amphip...
Source: European Journal of Pharmaceutics and Biopharmaceutics - January 8, 2019 Category: Drugs & Pharmacology Authors: Pan J, Palmerston Mendes L, Yao M, Filipczak N, Garai S, Thakur GA, Sarisozen C, Torchilin VP Tags: Eur J Pharm Biopharm Source Type: research

Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene‐dependent multidrug resistance
This study demonstrated the effectiveness of siRNA‐micelle for tumor‐targeted delivery, MDR reversal, and provided an effective strategy for the treatment of cancers that develop MDR. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2016.
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - July 12, 2016 Category: Materials Science Authors: Chun‐ge Zhang, Shu‐di Yang, Wen‐jing Zhu, Ben‐gang You, Yang Liu, Zhi‐qiang Yuan, Wei‐liang Chen, Ji‐zhao Li, Xiao‐feng Zhou, Chun Liu, Xue‐nong Zhang Tags: Original Research Report Source Type: research

Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene ‐dependent multidrug resistance
This study demonstrated the effectiveness of siRNA‐micelle for tumor‐targeted delivery, MDR reversal, and provided an effective strategy for the treatment of cancers that develop MDR. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2016.
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - July 12, 2016 Category: Materials Science Authors: Chun ‐ge Zhang, Shu‐di Yang, Wen‐jing Zhu, Ben‐gang You, Yang Liu, Zhi‐qiang Yuan, Wei‐liang Chen, Ji‐zhao Li, Xiao‐feng Zhou, Chun Liu, Xue‐nong Zhang Tags: Original Research Report Source Type: research

Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance
Publication date: 20 December 2017 Source:International Journal of Pharmaceutics, Volume 534, Issues 1–2 Author(s): Tingting Meng, Binbin Lu, Shihong Shao, Ming Yuan, Xuan Liu, Hong Yuan, Xuan Huang, Fuqiang Hu P-glycoprotein (P-gp) is a major efflux transporter overexpressed on multidrug resistant tumor cells and responsible for pumping drugs out. If anti-tumor drugs are given when P-gp level is low, satisfactory treatment efficiency may be achieved. Thus, a P-gp down-regulating siRNA (siMDR1) and doxorubicin (DOX) were applied to eliminate multidrug resistant breast cancer cells (MCF-7/ADR). A redox-responsive glucoli...
Source: International Journal of Pharmaceutics - November 6, 2017 Category: Drugs & Pharmacology Source Type: research

Mirror siRNAs loading for dual delivery of doxorubicin and autophagy regulation siRNA for multidrug reversing chemotherapy.
Abstract The multidrug resistance (MDR) which widely observed in multiple cancer types is responsible for the poor chemotherapy benefits of doxorubicin (Dox). Here in our study, Dox was firstly loaded into a scramble siRNA and then condensed by polyethyleneimine (PEI) 25k together with anti-autophagy siRNA, the obtained PEI/Si-D containing mirror RNAs was further coated with hyaluronic acid (HA) to shield the surface charge of PEI and offer tumor-homing property that finally developed a platform for effective cancer chemotherapy (HP/Si-D). Our results revealed that the obtained HP/Si-D was showed high stability an...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 22, 2020 Category: Drugs & Pharmacology Authors: Yang B, Hao A, Chen L Tags: Biomed Pharmacother Source Type: research

Targeting CD133 + laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles
Abstract Mesoporous silica nanoparticles (MSNs) represent a new form of drug nanocarrier with thermo/pH-coupling sensitivity and site-specificity. CD133+ Hep-2 laryngeal cancer cells are responsible for multidrug resistance due to elevated expression of ABCG2. Since positively charged nanoparticles could easily uptake nucleic acids, we examined the possibility of using this new drug delivery system to simultaneously deliver different chemotherapeutic drugs and siRNA targeting ABCG2. Our results demonstrated that both antitumor drugs and siRNA against ABCG2 were successfully delivered into CD133+ cancer cells by lo...
Source: Tumor Biology - September 9, 2015 Category: Cancer & Oncology Source Type: research

Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment
Publication date: 1 January 2019Source: Colloids and Surfaces B: Biointerfaces, Volume 173Author(s): Xiao-Lei Shi, Yuan Li, Lu-Ming Zhao, Lin-Wang Su, Gang DingAbstractOral cancer accounts for 95% of all maxillofacial malignant neoplasm. Presently, surgery and radiation (with and without chemotherapy) are the major treatments for oral cancer; however it met with limited therapeutic outcome. Overcoming the multidrug resistance and finding new therapeutic agents for oral cancer treatment are some of the serious challenges. Small molecule, TH287 potently and selectively inhibits the MTH1 protein in cells and could act as a ne...
Source: Colloids and Surfaces B: Biointerfaces - October 23, 2018 Category: Biochemistry Source Type: research

Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules
Biomaterials. 2022 Jan 17;281:121376. doi: 10.1016/j.biomaterials.2022.121376. Online ahead of print.ABSTRACTCombination therapy is a promising strategy for treating multidrug-resistant (MDR) cancers. Macromolecules such as antibodies and RNAs have been successfully used for targeted therapy owing to their high specificity. However, their application as therapeutics remains limited due to membrane impermeability and poor intracellular stability. Designing drug delivery systems capable of co-administering macromolecules is therefore crucial for advancing them as therapeutics for combination therapy. Herein, by using glutath...
Source: Biomaterials - January 22, 2022 Category: Materials Science Authors: Peiyan Yuan Fen Yang Si Si Liew Jiachang Yan Xiao Dong Jinfeng Wang Shubo Du Xin Mao Liqian Gao Shao Q Yao Source Type: research

Multifunctional Selenium Nanoparticles: Chiral Selectivity of Delivering MDR-siRNA for Reversal of Multidrug Resistance and Real-time Biofluorescence Imaging
In this paper, chiral selenium nanoparticles (L-SeNPs/D-SeNPs) modified with a dinuclear Ruthenium (II) complex were used to effectively deliver siRNA targeting the MDR1 gene. In this co-delivery system, the luminescent dinuclear Ruthenium (II) complex was developed to act as a gene carrier and anti-tumor drug, while offering luminescent imaging to follow the intracellular trafficking. Interestingly, Ru@L-SeNPs exhibited a stronger protein and pDNA affinity then Ru@D-SeNPs, indicating that chirality may have an effect on pDNA/siRNA binding and biocompatibility.
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - May 7, 2015 Category: Nanotechnology Authors: Qingchang Chen, Qianqian Yu, Yanan Liu, Dhairya Bhavsar, Licong Yang, Xiaofan Ren, Dongdong Sun, Wenjing Zheng, Jie Liu, Lan-mei Chen Source Type: research

Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
In this study, an acid-cleavable ketal containing poly (β-amino ester) (KPAE) was used to bind siBCL-2 and the KPAE/siBCL-2 complexes were further coated by epirubicin (EPI) containing lipid to form EPI/siBCL-2 dual loaded lipid-nanoparticles. The results showed that the average size of EPI/siBCL-2-MEND was about 120 nm, and the average zeta potential was about 41 mV. The encapsulation efficiency (EE) of EPI and siBCL-2 was 86.13% and 97.07%, respectively. EPI/siBCL-2 dual loaded lipid-nanoparticles showed enhanced inhibition efficiency than individual EPI-loaded liposomes on HepG2 cells by MTT assay. Moreover, wester...
Source: Artificial Cells, Nanomedicine and Biotechnology - April 12, 2017 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Hollow carbon nanospheres as a versatile platform for co-delivery of siRNA and chemotherapeutics
Publication date: September 2017 Source:Carbon, Volume 121 Author(s): Lingmin Zhang, Xinglong Yang, Ying Li, Wenfu Zheng, Xingyu Jiang The synergistic treatment with therapeutic nucleic acids and chemotherapeutics is considered to be a feasible strategy to overcome drug-resistant cancers. Herein, we constructed a novel amine dotted hollow carbon nanospheres (HCNs) to serve as a versatile platform for co-delivery of siRNA targeting multidrug resistance gene (MDR1) mRNA (siMDR1) and chemotherapeutics (Doxorubicin or Cisplatin) to fight drug-resistant cancers. The HCNs show enhanced loading capability of both siRNA and chemo...
Source: Carbon - May 27, 2017 Category: Materials Science Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Abstract Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collect...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 21, 2020 Category: Drugs & Pharmacology Authors: Song Y, Zhou B, Du X, Wang Y, Zhang J, Ai Y, Xia Z, Zhao G Tags: Biomed Pharmacother Source Type: research

Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors
p; V P Torchilin
Source: Gene Therapy - October 30, 2014 Category: Genetics & Stem Cells Authors: S EssexG NavarroP SabhachandaniA ChordiaM TrivediS MovassaghianV P Torchilin Source Type: research